Meropenem Stada

Meropenem, the active ingredient in Meropenem Stada, is a carbapenem antibiotic presented as an injectable solution for intravenous infusion. It is used to treat severe bacterial infections such as intra‑abdominal infections, urinary tract infections, pneumonia, meningitis, septicemia, and skin and soft‑tissue infections in hospitalized patients.

GNH USA supplies Meropenem Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem Stada is a broad‑spectrum carbapenem indicated for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: eradicates the causative pathogens and supports clinical recovery. - Complicated urinary tract infections: provides rapid bacterial clearance and symptom relief. - Nosocomial pneumonia: treats hospital‑acquired lung infections resistant to other agents. - Meningitis: penetrates the cerebrospinal fluid to eliminate meningitic organisms. - Septicemia: controls bloodstream infections and reduces mortality risk. - Skin and soft tissue infections: resolves deep tissue bacterial involvement.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Rash: erythematous skin eruption. - Infusion site phlebitis: local irritation at the IV site. - Vomiting: occasional emesis during treatment.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Thrombocytopenia: reduced platelet count requiring monitoring. - Renal impairment: worsening kidney function in susceptible individuals. - Hepatic enzyme elevation: transient increase in liver transaminases.

Careful assessment and monitoring are required before and during therapy. - Renal function: adjust dosing in patients with impaired clearance. - Seizure risk: monitor patients with a history of epilepsy or CNS disease. - Allergy: avoid in individuals with known carbapenem hypersensitivity. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concurrent nephrotoxic drugs: monitor renal parameters closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug‑drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may lower serum meropenem levels, increasing seizure risk. - Probenecid: can raise meropenem concentrations, heightening toxicity. - Aminoglycosides: additive nephrotoxic effect, requiring renal monitoring.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal clearance of meropenem. - Warfarin: monitor INR for possible anticoagulant effect changes. - Oral contraceptives: possible reduction in contraceptive efficacy, advise alternative protection.